Trial Profile
A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Azacitidine (Primary) ; Clofarabine (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Gemtuzumab ozogamicin (Primary) ; Tipifarnib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms AML-16
- 17 Jun 2021 Results from AML-16 and AML-18 for patients >60 years; identifying which patients benefit from RIC transplantation in CR1, presented at the 26th Congress of the European Haematology Association
- 22 Mar 2019 This trial has been completed in United Kingdom and Denmark, according to European Clinical Trials Database.
- 22 Mar 2019 This trial has been completed in United Kingdom and Denmark, according to European Clinical Trials Database.